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abstract
PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and
neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the
efﬁcacy and safety of GC4419, a superoxide dismutasemimetic, with placebo to reduce the duration, incidence,
and severity of severe OM (SOM).
PATIENTS AND METHODS A total of 223 patients (from 44 institutions) with locally advanced oral cavity or
oropharynx cancer planned to be treated with deﬁnitive or postoperative intensity-modulated RT (IMRT; 60 to
72 Gy [$ 50 Gy to two or more oral sites]) plus cisplatin (weekly or every 3 weeks) were randomly assigned to
receive 30 mg (n = 73) or 90 mg (n = 76) of GC4419 or to receive placebo (n = 74) by 60-minute intravenous
administration before each IMRT fraction. WHO grade of OM was assessed biweekly during IMRT and then
weekly for up to 8 weeks after IMRT. The primary endpoint was duration of SOM tested for each active dose level
versus placebo (intent-to-treat population, two-sided a of .05). The National Cancer Institute Common Ter-
minology Criteria for Adverse Events, version 4.03, was used for adverse event grading.
RESULTS Baseline patient and tumor characteristics as well as treatment delivery were balanced. With 90 mg
GC4419 versus placebo, SOM duration was signiﬁcantly reduced (P = .024; median, 1.5 v 19 days). SOM
incidence (43% v 65%; P = .009) and severity (grade 4 incidence, 16% v 30%; P = .045) also were improved.
Intermediate improvements were seen with the 30-mg dose. Safety was comparable across arms, with no
signiﬁcant GC4419-speciﬁc toxicity nor increase of known toxicities of IMRT plus cisplatin. The 2-year follow-up
for tumor outcomes is ongoing.
CONCLUSION GC4419 at a dose of 90 mg produced a signiﬁcant, clinically meaningful reduction of SOM
duration, incidence, and severity with acceptable safety. A phase III trial (ROMAN; ClinicalTrials.gov identiﬁer:
NCT03689712) has begun.
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INTRODUCTION
Approximately 70% of patients with head and neck
cancer (HNC) receiving concurrent cisplatin and ra-
diation experience severe oral mucositis (SOM), de-
ﬁned as grade 3 to 4 by the WHO scale.1-3 SOM causes
pain that potentially requires narcotics; adversely af-
fects nutrition (including requiring a feeding tube),
hydration, speech, swallowing, and bacteremia risk4,5;
leads to radiation treatment breaks, which compromise
tumor control6-8; and increases care costs, especially
from hospitalization and emergency room use.9,10
Treatment options for SOM are limited to symptom
management with topical agents and systemic
analgesics.11-19 No drugs are approved to reduce
SOM duration, incidence, or severity for patients with
solid tumors; palifermin is approved in the United
States for patients with hematologic malignancies
only.20,21 Consequently, SOMmanagement constitutes
an unmet clinical need.
The formation of reactive oxygen species, including
superoxide (O2*—), is a critical initiating event in the
biologic cascade that results in radiation-induced
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SOM.22 GC4419 is a superoxide dismutase mimetic that
rapidly and speciﬁcally converts O2*— to hydrogen peroxide
(H2O2),23 arresting the initiation of this cascade. In a phase
Ib/IIa trial in patients receiving standard concomitant cis-
platin and intensity-modulated radiation therapy (IMRT) for
HNC, SOM incidence, duration, and severity (WHO grade 4
oral mucositis [OM] incidence) seemed improved com-
pared with historical data when GC4419 was administered
at doses of 30 or 90 mg before each IMRT fraction.24 The
safety proﬁle of GC4419 was acceptable. The 1-year tumor
outcomes seemed consistent with expectations for IMRT
plus cisplatin alone. We now report the efﬁcacy and safety
results of a randomized, double-blind trial of 30 mg or
90 mg of GC4419 versus placebo in a similar trial
population.
PATIENTS AND METHODS
Trial Design and Oversight
This randomized, double-blind, placebo-controlled phase
IIb trial was sponsored and ﬁnancially supported by Galera
Therapeutics. The protocol was approved by each in-
stitution’s institutional review board and was registered at
ClinicalTrials.gov identiﬁer: NCT02508389). Investigators
obtained written informed consent from each participant.
Data were anonymized to protect the patients’ identities.
Patients
Eligible patients had stage III to IVb (according to American
Joint Committee on Cancer, seventh edition), non-
metastatic, oral cavity or oropharyngeal squamous cell
cancer, Eastern Cooperative Oncology Group performance
status of 2 or less, and planned treatment with standard
fractionation IMRT and concurrent cisplatin (80 to
100 mg/m2 every 3 weeks or 30 to 40 mg/m2 weekly)
administered deﬁnitively or after surgical resection. IMRT
plans had to include at least two oral mucosal sites (upper
or lower lip, right or left buccal mucosa, right or left ventral/
lateral oral tongue, ﬂoor of mouth, or soft palate) within the
cumulative 50-Gy isodose line and were centrally reviewed
by an independent radiation oncologist to conﬁrm protocol
adherence. Adequate marrow, renal, and hepatic functions
were required. Prophylactic percutaneous endoscopic
gastrostomy tube placement was allowed, but patients were
required to be able to eat soft solids at enrollment. Prior
induction chemotherapy or concurrent treatment with ni-
trates was not allowed.
Treatment and Assessments
IMRT was administered in daily 2.0- to 2.2-Gy fractions,
Monday through Friday, to a cumulative tumor dose of 60 to
72 Gy. Patients were randomly assigned in a 1:1:1 fashion
to receive 30 mg of GC4419, 90 mg of GC4419, or placebo;
each was administered intravenously in 250 mL of normal
saline over 60 minutes and ended within 60 minutes before
each radiation fraction. Enrollment was stratiﬁed by cis-
platin schedule and tumor human papillomavirus status
(p16 staining). Oral rinses—limited to sodium bicarbonate,
lidocaine, and antifungal agents—were permitted. Other
concurrent available or experimental systemic or topical
pharmaceuticals or devices or low-level laser therapy for
OM were excluded. Supportive care per ASCO guidelines
was encouraged.
OM was assessed by trained investigator-evaluators using
WHO criteria: grade 0, no mucositis; grade 1, pain and
erythema; grade 2, ulceration, able to eat solid food; grade
3, ulceration, able to eat only liquids; and grade 4, ulcer-
ation, inability to eat, requiring tube or parenteral feeding.
OM was assessed twice per week with at least 48 hours
between assessments during IMRT and weekly thereafter
for up to 8 weeks or until the WHO score was less than 2.
OM assessment training and quality control were per-
formed by Clinical Assistance Programs (Framingham, MA)
to ensure that (1) all oral assessments were performed
consistently using standardized questions, oral cavity ex-
amination technique and order, and data collection; and
(2) WHO grade scoring was correctly assigned per as-
sessment ﬁndings for all OM assessments. To reduce the
variability in assessing a patient’s diet, investigator-
evaluators were trained carefully to elucidate whether di-
etary compromise was because of oral pain. If not, and if
the diet was compromised by confounding factors (eg,
dysgeusia, edentulism, nausea, mucous, throat pain,
functional dysphagia), the WHO score was determined on
the basis of what the patient said they could eat absent
these factors. Accuracy and consistency of WHO scores
were evaluated within a few days of each assessment.
Inconsistent or incomplete mucositis assessments were
queried before ﬁnal WHO scores were entered into the
database.
Adverse events were assessed using the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.03. Dose reduction of 25% of GC4419 or placebo
was required for grade 3 ﬂushing, grade 2 or greater hy-
potension within 2 hours after the start of GC4419 or
placebo infusion, grade 3 or 4 infusion reaction with
GC4419 or placebo, or grade 4 vomiting despite optimal
antiemetic therapy per current guidelines. Two dose re-
ductions were permitted per patient, and the drug was
discontinued if the patient was still unable to tolerate
treatment. Tumor progression and survival were assessed
every 3 months in the ﬁrst year, and every 4 months in the
second year, after IMRT. Data collected for exploratory
assessments included the following: during IMRT, the Oral
Mucositis Daily Questionnaire (OMDQ) responses,4 opioid
use, insertion of gastrostomy tubes, use and complications
of indwelling venous access catheters, and unplanned
visits or hospitalizations; and in the 2 years after IMRT,
measurement of trismus and visual analog scale of xero-
stomia. Peripheral blood specimens were collected before
and during IMRT for future exploratory assessments of
circulating cytokines and gene expression patterns.
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Statistical Methods
Efﬁcacy analyses were conducted on the intent-to-treat
population (all randomly assigned patients). The primary
efﬁcacy endpoint was SOM duration, deﬁned as the
number of days from the ﬁrst to the last occurrence of SOM,
including any intervening days with grade 2 or lower OM.
Patients with no WHO score greater than 2 had, by deﬁ-
nition, an SOM duration of 0 days. Duration in patients with
unresolved SOM as of the last evaluation was imputed as
the median duration among patients in the same treatment
arm with at least that duration. For patients without ob-
served SOM but with incomplete follow-up, duration was
imputed as the median duration among patients in the
same treatment arm who were free of SOM for at least that
length of follow-up. SOM duration in each active arm was
compared separately with that of the placebo arm using the
nonparametric van Elteren test.25
Secondary endpoints, tested using the Cochran-Mantel-
Haenszel test, were SOM incidence at any time during
IMRT or through 60 Gy of IMRT and severity (grade 4
incidence) at any time during IMRT. Testing was performed
in a conditional, sequential fashion: SOM duration, 90 mg
versus placebo; then SOM duration, 30 mg versus placebo;
then secondary endpoints, with formal testing proceeding
as long as the P value was .05 or less. A sample size of 72
patients per group provided approximately 80% power with
a two-sided type I error rate of .05 for each treatment arm’s
comparison with placebo. Calculations assumed a median
SOM duration of 0 days in the treatment arms compared
with 28 days in the placebo arm, with 40% SOM incidence
in each treatment arm compared with 65% in the placebo
arm. Safety was assessed for all randomly assigned patients
who received at least one dose of GC4419 or placebo.
RESULTS
Forty-four US and Canadian sites enrolled 223 patients,
217 of whom received at least one infusion of GC4419 or
placebo (CONSORT diagram, Fig 1). Baseline patient
characteristics were balanced across the three treatment
arms (Table 1), as was delivery of IMRT plus cisplatin,
which did not seem to be compromised with the addition of
GC4419 (Table 2). Radiation therapy (RT) plan adherence
to the protocol was conﬁrmed in all cases. The initially
assigned WHO score was correct—that is, consistent with
source data—in 3,617 (95.3%) of all 3,794OMassessments
throughout the trial; all errors were queried and corrected to
ensure 100% accuracy of scoring. Approximately 80% of
patients in each treatment arm had complete OM follow-up;
roughly 10% of patients were lost to follow-up before
resolution of SOM to a WHO score of 0 or 1, and 10% were
lost to follow-up without ever experiencing SOM.
Efﬁcacy
SOM duration was signiﬁcantly reduced among patients
receiving 90 mg of GC4419 compared with those receiving
placebo (P, .024 using the van Elteren test; Table 3). The
median SOM duration in the 90-mg arm also was reduced
versus placebo—1.5 days versus 19 days—which re-
ﬂected, in part, a 34% relative reduction of SOM incidence
at any time during IMRT (43% v 65%; nominal P = .009)
and a corresponding increase in the number of patients
with an SOM duration of 0 days. Severity (grade 4 OM
incidence at any time during IMRT; 16% v 30%; nominal
P = .045) and SOM incidence through 60 Gy (37% v 58%;
nominal P = .010) also were lower for the 90-mg group than
for the placebo group. Cumulative SOM incidence was
progressively lower in the 90-mg arm than the placebo arm
at serial RT delivery landmarks (30 Gy, 40 Gy, 50 Gy, 60 Gy;
Fig 2). Primary and secondary efﬁcacy results for the 30-mg
group versus placebo were intermediate (SOM duration,
8 days [P = .163]; SOM incidence thru 60 Gy, 40%
[P = .026]).
We also asked if GC4419 tempered the course and severity
of SOM even if it failed to completely prevent it. In the
subgroup of patients who had at least 1 day of SOM, visual
inspection of individual patient data (Fig 3) indicated re-
duction of SOM overall and of grade 4 OM with 90 mg of
Patients randomly assigned 
(N = 223)
from 44 US and Canadian sites
ITT
(primary analysis)
Placebo
(n = 74)
GC4419 30 mg
(n = 73)
GC4419 90 mg
(n = 76)
Treated
(safety population)
GC4419 30 mg
(n = 73)
GC4419 90 mg
(n = 72)
(n = 2) (n = 0) (n = 4)
Placebo
(n = 72)
Random
assignment
failures:
not treated
FIG 1. CONSORT diagram: patient random
assignment. ITT, intent to treat.
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TABLE 1. Baseline Patient Characteristics
Characteristic
No. (%) of Patients
Placebo
(n = 74)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 76)
All Patients
(N = 223)
Sex
Male 64 (86) 64 (88) 64 (84) 192 (86)
Female 10 (14) 9 (12) 12 (16) 31 (14)
Median age, years 58 58 56 57
Age range, years 33-77 34-77 30-84 30-84
ECOG PS
0 50 (68) 47 (64) 50 (66) 147 (66)
1 24 (32) 25 (34) 22 (29) 71 (32)
2 0 1 (1) 4 (5) 5 (2)
Tumor site
Oropharyngeal 56 (76) 62 (84) 54 (71) 172 (77)
Oral cavity 14 (19) 9 (12) 17 (22) 40 (18)
Unknown 4 (5) 2 (4) 5 (6) 11 (5)
Treatment type
Deﬁnitive 59 (80) 56 (77) 57 (75) 172 (77)
Postoperative treatment 15 (20) 17 (23) 19 (25) 51 (23)
TNM stage
0-II 3 (4) 0 4 (6) 7 (3)
III 6 (8) 8 (11) 6 (8) 20 (9)
IVa 60 (81) 63 (86) 59 (78) 182 (82)
IVb 3 (4) 2 (3) 7 (9) 12 (5)
Unknown/not reported 2 (3) 0 0 2 (1)
Tumor HPV status
Positive 53 (72) 53 (73) 54 (71) 160 (72)
Negative 21 (28) 20 (27) 22 (29) 63 (28)
Cisplatin schedule
Every 3 weeks 28 (38) 27 (37) 30 (39) 85 (38)
Weekly 46 (62) 46 (63) 46 (61) 138 (62)
No. of normal mucosa sites $ 50 Gy
2 4 (5) 10 (14) 7 (9) 21 (9)
3-4 41 (55) 35 (48) 41 (54) 117 (52)
$ 5 29 (39) 28 (39) 28 (37) 85 (38)
Tobacco use
Never 23 (31) 25 (34) 17 (22) 65 (29)
Past 40 (54) 37 (51) 43 (57) 120 (54)
Current 11 (15) 11 (15) 16 (21) 38 (17)
Current alcohol use
Yes 39 (53) 32 (44) 44 (58) 115 (52)
No 35 (47) 41 (56) 32 (42) 108 (48)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus.
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GC4419 compared with placebo. Consistent with this, the
persistence of grade 4 OM was less for 90 mg of GC4419
than for placebo (Appendix Fig A1, online only).
The duration and incidence of SOM in the active or placebo
arms were not affected by cisplatin schedule (weekly v
every 3 weeks), tumor human papillomavirus status, de-
ﬁnitive versus postoperative IMRT, or patient-reported
smoking status (data not shown). The incidence of ulcer-
ative OM (ie, OM WHO grade 2 or greater) was comparable
across the treatment arms.
Safety
The overall adverse event proﬁle in each of the GC4419
arms was comparable to that in the placebo arm and
seemed consistent with the known toxicities of IMRT plus
cisplatin when either events of all grades (Appendix Table A1,
online only) or grades 3 or greater (Appendix Table A2,
online only) were considered. Eight percent of patients,
comparably distributed across the three arms, required
dose reductions for adverse events.
Hematologic toxicities, particularly lymphopenia, attribut-
able to cisplatin and IMRT were the most prominent tox-
icities. These were not increased in incidence or severity by
the addition of GC4419.
Other speciﬁc adverse events attributable to cisplatin—
severe nausea or vomiting, increased creatinine, or tinnitus—
did not seem more frequent or severe with the addition of
GC4419 (Table 4). Transient grade 3 hypokalemia, attrib-
utable to cisplatin as well as other factors, such as GI loss and
poor oral intake, occurred in 15% of patients in the 90-mg
arm versus 11% of patients in the 30-mg arm and 6% in the
placebo arm. This adverse event was corrected with supple-
mentation and was otherwise without clinical consequence.
Because superoxide reacts with nitric oxide, reduction of
superoxide by GC4419 is expected to potentiate the activity
of nitric oxide. This was reﬂected (Table 4) in an apparent
dose-dependent increase in low-grade hypotension, with-
out frank syncope, and in mild perioral tingling, both of
which were transient and resolved promptly after GC4419
infusion (Table 4). One patient in the 90-mg arm who was
taking metoprolol for pre-existing hypertension dis-
continued GC4419 in association with grade 3 orthostatic
hypotension. However, overall, grade 3 hypotension was
not increased with GC4419 compared with placebo.
An indwelling venous access device was used to facilitate
repeated GC4419 or placebo infusion for 196 (90%) of 217
patients; 155 (71%) of the 217 patients had an implantable
port. There were 0.09 device-related adverse events per
TABLE 2. Treatment Delivery
Variable
Patients by Group (N = 217)
Placebo
(n = 72)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 72)
Mean/median (range) total IMRT dose, Gy 66.3/70 (11-70) 64.8/70 (4-72) 65.7/70 (11-74)
No. (%) receiving $ 60 Gy 68 (94) 65 (89) 66 (92)
No. (%) with RT treatment breaks $ ﬁve consecutive fractions 6 (8) 1 (1) 5 (7)
No./total No. (%) with cisplatin total dose delivered $ 200 mg/m2
Every 3 weeks 25/28 (89) 23/27 (79) 27/31 (87)
Weekly 35/44 (80) 31/44 (70) 32/41 (78)
Planned GC4419/placebo doses received, %
Median 100 97 100
Mean 93 89 90
Abbreviations: IMRT, intensity-modulated radiation therapy; RT, radiation therapy.
TABLE 3. Efﬁcacy Results
Parameter Placebo 30 mg GC4419 90 mg GC4419
Relative Reduction, 90 mg
GC4419 v Placebo (%)
SOM duration v placebo, van Elteren test Reference P = .163 P = .024* —
Median SOM duration, days 19 8 1.5 92
Mean (SD) SOM duration, days 24.8 (25.0) 18.4 (21.5) 16.1 (23.3) NA
SOM (grade 3 or 4) incidence, %
Through IMRT 65 60 43 34
Through 60 Gy 58 40 37 36
Grade 4 OM incidence through IMRT, % 30 21 16 47
Abbreviations: IMRT, intensity-modulated radiation therapy; NA, not applicable; OM, oral mucositis; SD, standard deviation; SOM, severe oral mucositis.
*Statistically signiﬁcant.
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100 days of use. These results were similar in the three
study arms.
Tumor Outcomes
At the time of this report, 2-year post-IMRT follow-up
is ongoing for locoregional control, distant metastasis,
progression-free survival, and overall survival. In the in-
terim, through 1 year, the numbers of observed deaths or
progression events (locoregional failures and distant metas-
tases) were similar in the three arms (data not shown). Full,
formal assessment awaits completion of the follow-up period.
Exploratory Evaluations
Among 112 patients who had at least one observation of
SOM and who took at least one dose of a narcotic from the
start through the end of IMRT, the median total morphine
equivalent per patient was 1,410 mg for placebo (n = 40),
1,053 mg for 30 mg of GC4419 (n = 40), and 752 mg for
90 mg of GC4419 (n = 32). Overall, 188 (87%) of the 217
treated patients (a similar percentage in all three arms) took
at least one dose of a narcotic. The WHO score was 0 for
116 (62%) of these 188 patients and was less than 3 for
179 (95%) of the 188 patients at the time of ﬁrst narcotic
0
10
20
30
40
50
60
70
 30  40  50  60
15 16
13
27 29
20
42
34
29
58
40
37
Placebo (n = 74)
30 mg (n = 73)
90 mg (n = 76) 
%
Gy
FIG 2. Cumulative severe oral mucositis (WHO grade 3 or 4) in-
cidence (%) at progressive intensity-modulated radiation therapy
delivery landmarks (Gray cutoffs).
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FIG 3. Swimmer plot of severe oral mucositis scores for the subsets of patients in (left) the placebo arm (n = 45) or (right) the 90-mg arm (n = 35) who had
at least oneWHO oral mucositis score of grade 3 or 4. Each horizontal lane represents the experience of an individual patient. Time on radiation therapy or
after radiation therapy is indicated at the top, for which the vertical line denotes the end of intensity-modulated radiation therapy. Yellow, WHO grade 3;
red, WHO grade 4; purple, WHO grade 0 to 2. WHO scoring was done twice per week during radiation therapy, then once per week after radiation therapy
in patients who returned for follow-up for up to 8 weeks or until the WHO score was 0 or 1.
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dose; this result also was comparable across the three
arms. The median patient-reported subjective mouth and
throat soreness, on the 5-point (0 to 4) OMDQ scale, was
0.5 for placebo and 1.0 for each GC4419 arm at baseline
and increased to 2.0 for all three arms by week 4 of
treatment.
Gastrostomy tube use varied by institutional practice.
Overall, gastrostomy tubes were placed in 145 (67%) of
217 treated patients, and, as expected, gastrostomy use
seemed to track with maximum WHO score. Placement
was prophylactic (ie, placed before IMRT day 1) for 96
patients (placebo, n = 34; 90-mg arm, n = 28) and
emergent (ie, on or after IMRT day 1) for 49 patients
(placebo, n = 16; 90-mg arm, n = 13). Gastrostomy tubes
were used for feeding at least once in 127 patients (pla-
cebo, n = 42; 90-mg arm, n = 36). Weight loss was
comparable across the three arms (data not shown). The
2-year follow-up for xerostomia and trismus is in progress.
DISCUSSION
Oxidative stress plays a critical initiating role in the path-
ogenesis of OM. RT causes rapid production of large
amounts of O2*—, which overwhelms the capacity of native
superoxide dismutase enzymes to convert the O2*— to H2O2
and so triggers signaling pathways in the submucosa,
which results in apoptosis of epithelial stem cells, conse-
quent loss of epithelial renewal, atrophy, and mucosal
ulceration.22 Unlike palliative measures, the dismutase mi-
metic GC4419 is hypothesized to arrest this process at its
initiation. The results of this trial extend prior nonclinical and
clinical observations, which suggest that GC4419 protects
normal oral mucosa from damage associated with RT for
locally advancedHNC. In a phase Ib/IIa trial, SOM incidence,
duration, and severity (WHO grade 4 OM incidence) seemed
reduced compared with historical expectations with either
the 30-mg or 90-mg doses of GC4419, indicating that ad-
ditional evaluation of both doses was warranted.24
In this trial, GC4419 at the 90-mg dose reduced SOM du-
ration compared with placebo. SOM incidence and severity
(grade 4 OM incidence) were reduced by 34% and 47%,
respectively. SOM results in the placebo armwere consistent
with historical data, whereas results for 90 mg of GC4419
seem clinically signiﬁcant and favorable in the context of
historical data.1,2 Results for the 30-mg arm were in-
termediate between those for the 90-mg and placebo arms,
consistent with a dose-response relationship for efﬁcacy.
The WHO OM score has the advantage of combining an-
atomic, functional, and symptomatic elements of OM and,
when assessed by trained investigator-evaluators after
a formal training process, is a well-deﬁned, consistently and
TABLE 4. Speciﬁc Toxicities of Interest Thought Attributable to Cisplatin or GC4419
Variable
No. (%) of Patients
Placebo 30 mg GC4419 90 mg GC4419
Total No. of treated patients 72 73 72
Any grade 3-4 event 68 (94) 70 (96) 69 (96)
Nausea
Grade 1-2 54 (75) 50 (68) 59 (82)
Grade 3-4 9 (13) 11 (15) 8 (11)
Vomiting
Grade 1-2 34 (47) 38 (52) 35 (49)
Grade 3 8 (11) 3 (4) 6 (8)
Grade 3 creatinine elevation 2 (3) 3 (4) 4 (6)
Grade 1-2 tinnitus 19 (26) 19 (26) 15 (21)
Hypotension/orthostatic hypotension
Grade 1 1 (1) 2 (3) 7 (10)
Grade 2 6 (8) 11 (15) 9 (13)
Grade 3 4 (6) 3 (4) 3 (4)
Syncope
Grade 1-2 1 (1) 1 (1) 1 (1)
Grade 3 3 (4) 3 (4) 4 (6)
Dizziness
Grade 1 8 (11) 12 (16) 17 (24)
Grade 2 1 (1) 3 (4) 2 (3)
Grade 3 0 1 (1) 0
Facial tingling/paresthesia (all grade 1) 11 (15) 7 (10) 15 (21)
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systematically applied measure of SOM that has become
widely accepted for use in clinical trials of interventions
intended to reduce SOM. As such, conﬁrmation of reduced
SOM by the WHO score in appropriately designed clinical
trials may be considered strong evidence of efﬁcacy.
GC4419 did not seem to increase the known toxicity of
IMRT plus cisplatin at either dose. Toxicity attributable
speciﬁcally to GC4419 was modest and transient, resolved
with cessation or dose reduction of GC4419 infusion, and
did not compromise treatment with GC4419 or chemo-
radiation. These effects likely are the result of potentiation
of nitric oxide by GC4419, as previously reported with this
class of compounds.26
Our exploratory data suggest that GC4419 may be asso-
ciated with a decreased need for narcotic use. This requires
more assessment, however; patients took narcotics for
reasons other than OM, and no requirements or guidelines
for narcotic prescribing and administration were used.
Other exploratory assessments (gastrostomy tube use,
OMDQ) are subject to similar limitations, such as different
institutional practices, multiple clinical factors (eg, mucous
production, dysgeusia, xerostomia, swallowing dysfunc-
tion) affecting outcomes, or broad effects of the multi-
modality disease management for this patient population.
It is critical that any supportive cancer care intervention not
antagonize anticancer efﬁcacy, and 1-year tumor outcomes
from the prior phase Ib/IIa trial did not suggest compromise
with GC4419.24 The 2-year follow-up results for this phase
IIb trial are still pending.
Mechanistically, GC4419 is expected not to antagonize
tumor response to chemoradiotherapy and may, under
certain conditions, enhance it. Normal and cancer cells
respond to O2*— and H2O2 differently. Speciﬁcally, normal
cells tend to be more sensitive to elevations in superoxide,
whereas moderate elevations in superoxide may serve to
promote tumor growth. Conversely, signiﬁcant increases in
hydrogen peroxide ﬂux are less well tolerated by cancer
cells than by normal cells.27 Thus, GC4419, by converting
RT-induced O2*— into H2O2, should reduce normal tissue
toxicity while maintaining anticancer efﬁcacy. Nonclinical
data have demonstrated anticancer synergy between
GC4419 and higher dose-fraction RT regimens, as used in
stereotactic body RT, with that synergy reversible in an
inducible-catalase (which efﬁciently removes H2O2) tumor
model.28 These data form the basis for an ongoing phase I/II
clinical trial of GC4419 plus stereotactic body RT for pa-
tients with locally advanced pancreatic cancer (Clinical-
Trials.gov identiﬁer: NCT03340974).
SOM remains a devastating toxicity, inadequately de-
scribed by warning patients of mouth sores that may
complicate their therapy, for which treatment options
are limited. Our results demonstrate the potential for
GC4419, an agent intended to interrupt SOM pathogen-
esis, to reduce the duration, incidence, and severity of
radiation-induced SOM and thereby become an impor-
tant new tool in the management of this adverse event in at-
risk patients. Accordingly, a phase III conﬁrmatory trial,
the ROMAN trial, has been initiated (ClinicalTrials.gov
identiﬁer: NCT03689712).
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Sanjiv S. Agarwala, MD, St. Luke’s Cancer Center and Temple Uni-
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IA; Roberto Arevalo-Araujo, MD, Pasco Pinellas Cancer Center, Hol-
iday, FL; Voichita Bar Ad, MD, Thomas-Jefferson University Hospital,
Philadelphia, PA; Maura Barry, MD, The University of Vermont Cancer
Center, Burlington, VT; Ariel Birnbaum, MD, Rhode Island Hospital,
Providence, RI; Dukagjin Blakaj, MD, PhD, Ohio State University,
Columbus, OH; Marcelo Bonomi, MD, Wake Forest Baptist Health,
Winston-Salem, NC; Leander Cannick III, MD, Anmed Health Cancer
Center, Anderson, SC; Daniel Clayburgh, MD, PhD, VA Portland Health
Care, System, Portland, OR; Patrick Cobb, MD, FACP, St Vincent
Frontier Cancer Center, Billings, MT; Kevin Collins, MD, JD, Fowler
Family Center for Cancer Care, Jonesboro, AR; Kyle Colvett, MD,
Mountain States Health Alliance Research Department, Johnson City,
TN; Amy Curtis, MD, Spartanburg Medical Center, Spartanburg, SC;
Bianca de Souza, MD, Henry Ford Allegiance Health, Jackson, MI;
Neal Dunlap, MD, University of Louisville, Louisville, KY; Elizabeth
Feldman, MS, DMD, UF Health Cancer Center at Orlando Health,
Orlando, FL; Madhu Garg, MD, Monteﬁore Medical Center, Bronx, NY;
SharonM. Gordon, DDS, MPH, PhD, School of Dental Medicine at East
Carolina University, Greenville, NC; Alan Gowan, DO, Scott & White
Memorial Hospital and Clinic, Temple, TX; Charles Holladay, MD,
Charleston Cancer Center, Charleston, SC; Anshu K. Jain, MD, Ash-
land-Bellefonte Cancer Center, Ashland, KY and Yale School of
Medicine; Joseph Kelley, MD, PhD, University of Tennessee Medical
Center, Knoxville, TN; Vernon King, MD, St Mary’s Regional Cancer
Center, Grand Junction, CO; Clint Daniel Kingsley, MD, Ellis Fischel
Cancer Center - University of Missouri, Columbia, MO; Philip Kovoor,
MD, Texas Oncology, Plano West, Plano, TX; Ganesh Kudva, Henry
Ford Allegiance Health, Jackson, MI; Arielle Lee, MD, Tyler Hema-
tology-Oncology, Tyler, TX; Christopher Lee, MD, Cancer Care
Northwest, Spokane, WA; Steve P. Lee, MD, PhD, Long Beach Veteran
Affairs Healthcare System, Long Beach, CA; Ronald Maggiore, MD, VA
Portland Health Care System, Portland, OR; Maria Matsangou, MD,
Northwestern University, Chicago, IL; DouglasMiller, MD, Jersey Shore
University Medical Center, Neptune, NJ; Rex Mowat, MD, Toledo
Clinic Cancer Center, Toledo, OH; Rupali Nabar, MD, UC Irvine
Medical Center, Orange, CA; Chaitali Nangia, MD, UC Irvine Medical
Center, Orange, CA; Jorge Nieva, MD, USC Norris Cancer Center, Los
Angeles, CA; Celine Ord, MD, University of Arizona Cancer Center at
Dignity Health St Joseph’s, Phoenix, AZ; Shymal Patel, MD, University
of Arizona Cancer Center at Dignity Health St Joseph’s, Phoenix, AZ;
Abhinand Peddada, MD, Renown Regional Medical Center, Reno, NV;
Mercedes Porosnicu, MD, Wake Forest Baptist Health, Winston-
Salem, NC; Waqas Rehman, Hunterdon Hematology Oncology, LLC,
Flemington, NJ; Deborah P. Saunders, DND, B.Sc, Northeast Cancer
Centre of Health Sciences North Northern Ontario School of Medicine,
Sudbury, ON, Canada; Khalil Sultanem, MD, Jewish General Hospital,
Montreal, QC, Canada; Michael Trendle, MD, Ellis Fischel Cancer
Center - University of Missouri, Columbia, MO; Madhavi Venigalla, MD,
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FIG A1. Numbers of patients with grade 4 oral mucositis of progressively greater length, 90 mg v placebo.
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TABLE A1. AEs Experienced by 10 or More ($ 5%) of All Patients
AE Data
No. (%) of Patients by Group
Placebo
(n = 72)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 72)
All Patients
(N = 217)
Total No. of TEAEs 1,847 2,055 2,189 6,091
Any TEAEs 72 (100) 73 (100) 72 (100) 217 (100)
TEAE by preferred term
Lymphopenia 64 (89) 67 (92) 63 (88) 194 (89)
Nausea 54 (75) 50 (68) 59 (82) 163 (75)
Fatigue 50 (69) 44 (60) 47 (65) 141 (65)
Oropharyngeal pain 46 (64) 46 (63) 44 (61) 136 (63)
Constipation 38 (53) 43 (59) 46 (64) 127 (59)
Radiation skin injury 34 (47) 37 (51) 38 (53) 109 (50)
Vomiting 34 (47) 38 (52) 35 (49) 107 (49)
Dysgeusia 35 (49) 40 (55) 31 (43) 106 (49)
Dysphagia 31 (43) 31 (42) 34 (47) 96 (44)
Weight decreased 25 (35) 29 (40) 32 (44) 86 (40)
Oral candidiasis 21 (29) 33 (45) 31 (43) 85 (39)
Leukopenia 28 (39) 27 (37) 28 (39) 83 (38)
Diarrhea 28 (39) 31 (42) 22 (31) 81 (37)
Dehydration 23 (32) 27 (37) 30 (42) 80 (37)
Decreased appetite 23 (32) 22 (30) 31 (43) 76 (35)
Headache 17 (24) 16 (22) 24 (33) 57 (26)
Neutropenia 19 (26) 18 (25) 17 (24) 54 (25)
Hiccups 17 (24) 17 (23) 19 (26) 53 (24)
Hypokalemia 13 (18) 19 (26) 21 (29) 53 (24)
Tinnitus 19 (26) 19 (26) 15 (21) 53 (24)
Dysphonia 18 (25) 16 (22) 16 (22) 50 (23)
Hypomagnesaemia 16 (22) 16 (22) 18 (25) 50 (23)
Anemia 9 (13) 20 (27) 17 (24) 46 (21)
Dizziness 9 (13) 16 (22) 19 (26) 44 (20)
Pyrexia 15 (21) 15 (21) 13 (18) 43 (20)
Candida infection 12 (17) 13 (18) 11 (15) 36 (17)
Hypotension 7 (10) 12 (16) 17 (24) 36 (17)
Cough 11 (15) 13 (18) 8 (11) 32 (15)
Gastroesophageal reﬂux disease 11 (15) 9 (12) 12 (17) 32 (15)
Chills 10 (14) 10 (14) 11 (15) 31 (14)
Insomnia 8 (11) 11 (15) 11 (15) 30 (14)
Hypertension 10 (14) 7 (10) 12 (17) 29 (13)
Dry skin 11 (15) 5 (7) 12 (17) 28 (13)
Hyponatremia 10 (14) 11 (15) 7 (10) 28 (13)
Paresthesia 9 (13) 7 (10) 12 (17) 28 (13)
Dyspepsia 6 (8) 13 (18) 8 (11) 27 (12)
Dyspnea 8 (11) 8 (11) 9 (13) 25 (12)
Acute kidney injury 8 (11) 10 (14) 5 (7) 23 (11)
Neck pain 7 (10) 7 (10) 9 (13) 23 (11)
(continued on following page)
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TABLE A1. AEs Experienced by 10 or More ($ 5%) of All Patients (continued)
AE Data
No. (%) of Patients by Group
Placebo
(n = 72)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 72)
All Patients
(N = 217)
Thrombocytopenia 10 (14) 5 (7) 7 (10) 22 (10)
Anxiety 7 (10) 8 (11) 6 (8) 21 (10)
Upper-airway cough syndrome 7 (10) 9 (12) 5 (7) 21 (10)
Pruritus 6 (8) 7 (10) 7 (10) 20 (9)
Salivary hypersecretion 3 (4) 6 (8) 11 (15) 20 (9)
Edema, peripheral 6 (8) 5 (7) 8 (11) 19 (9)
Alopecia 3 (4) 5 (7) 9 (13) 17 (8)
Electrocardiogram QT prolonged 4 (6) 6 (8) 5 (7) 15 (7)
Odynophagia 4 (6) 6 (8) 5 (7) 15 (7)
Stoma site pain 6 (8) 8 (11) 1 (1) 15 (7)
Ear pain 4 (6) 5 (7) 5 (7) 14 (6)
Febrile neutropenia 3 (4) 5 (7) 6 (8) 14 (6)
Hypocalcemia 5 (7) 3 (4) 5 (7) 13 (6)
Pain in jaw 8 (11) 2 (3) 3 (4) 13 (6)
Renal disorder 4 (6) 4 (5) 5 (7) 13 (6)
Syncope 4 (6) 4 (5) 5 (7) 13 (6)
Asthenia 5 (7) 3 (4) 4 (6) 12 (6)
Flushing 2 (3) 8 (11) 2 (3) 12 (6)
Hearing impaired 4 (6) 6 (8) 2 (3) 12 (6)
Hypophosphatemia 6 (8) 3 (4) 3 (4) 12 (6)
Urinary tract infection 2 (3) 4 (5) 6 (8) 12 (6)
Depression 6 (8) 1 (1) 4 (6) 11 (5)
Hyperglycemia 3 (4) 3 (4) 5 (7) 11 (5)
Erythema 5 (7) 1 (1) 4 (6) 10 (5)
Face edema 4 (6) 3 (4) 3 (4) 10 (5)
Increased upper airway secretion 2 (3) 3 (4) 5 (7) 10 (5)
Mucosal infection 3 (4) 5 (7) 2 (3) 10 (5)
Orthostatic hypotension 4 (6) 4 (5) 2 (3) 10 (5)
NOTE. All events of all grades are included without regard to reported causality.
Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse event.
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TABLE A2. AEs of Grade 3 or Greater Experienced by Two or More Patients ($ 1%)
AE Data
No. (%) of Patients by Group
Placebo
(n = 72)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 72)
All Patients
(N = 217)
Total No. of grade $ 3 TEAEs 391 417 394 1,202
Any grade $ 3 TEAE 68 (94) 71 (97) 69 (96) 208 (96)
TEAE by preferred term
Lymphopenia 64 (89) 67 (92) 63 (88) 194 (89)
Leukopenia 27 (38) 24 (33) 28 (39) 79 (36)
Neutropenia 15 (21) 17 (23) 13 (18) 45 (21)
Dysphagia 14 (19) 12 (16) 13 (18) 39 (18)
Anemia 7 (10) 15 (21) 12 (17) 34 (16)
Decreased appetite 10 (14) 11 (15) 8 (11) 29 (13)
Hyponatremia 10 (14) 11 (15) 7 (10) 28 (13)
Nausea 9 (13) 11 (15) 8 (11) 28 (13)
Dehydration 10 (14) 7 (10) 8 (11) 25 (12)
Hypokalemia 4 (6) 8 (11) 11 (15) 23 (11)
Oropharyngeal pain 3 (4) 12 (16) 6 (8) 21 (10)
Vomiting 8 (11) 3 (4) 6 (8) 17 (8)
Febrile neutropenia 3 (4) 5 (7) 5 (7) 13 (6)
Hypertension 5 (7) 3 (4) 5 (7) 13 (6)
Hyperglycemia 3 (4) 3 (4) 5 (7) 11 (5)
Syncope 3 (4) 3 (4) 4 (6) 10 (5)
Weight decreased 3 (4) 4 (5) 3 (4) 10 (5)
Acute kidney injury 2 (3) 3 (4) 4 (6) 9 (4)
Hypophosphatemia 5 (7) 2 (3) 2 (3) 9 (4)
Hypotension 4 (6) 2 (3) 3 (4) 9 (4)
Radiation skin injury 4 (6) 2 (3) 2 (3) 8 (4)
Hypocalcemia 2 (3) 2 (3) 3 (4) 7 (3)
Liver disorder 2 (3) 3 (4) 2 (3) 7 (3)
Malnutrition 2 (3) 2 (3) 3 (4) 7 (3)
Thrombocytopenia 3 (4) 2 (3) 2 (3) 7 (3)
Fatigue 4 (6) 1 (1) 1 (1) 6 (3)
Hypoxia 3 (4) 3 (4) 0 (0) 6 (3)
Sepsis 3 (4) 2 (3) 1 (1) 6 (3)
Headache 3 (4) 1 (1) 1 (1) 5 (2)
Lung infection 2 (3) 1 (1) 2 (3) 5 (2)
Pneumonia 3 (4) 0 (0) 2 (3) 5 (2)
Pyrexia 1 (1) 3 (4) 1 (1) 5 (2)
Cytopenia 2 (3) 1 (1) 1 (1) 4 (2)
Oral candidiasis 3 (4) 0 (0) 1 (1) 4 (2)
Pharyngitis 2 (3) 1 (1) 1 (1) 4 (2)
Stoma site infection 2 (3) 0 (0) 2 (3) 4 (2)
Asthenia 1 (1) 1 (1) 1 (1) 3 (1)
Constipation 1 (1) 1 (1) 1 (1) 3 (1)
Lymphocytosis 1 (1) 2 (3) 0 (0) 3 (1)
(continued on following page)
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TABLE A2. AEs of Grade 3 or Greater Experienced by Two or More Patients ($ 1%) (continued)
AE Data
No. (%) of Patients by Group
Placebo
(n = 72)
30 mg GC4419
(n = 73)
90 mg GC4419
(n = 72)
All Patients
(N = 217)
Pain 0 (0) 1 (1) 2 (3) 3 (1)
Renal disorder 1 (1) 1 (1) 1 (1) 3 (1)
Urinary tract infection 0 (0) 2 (3) 1 (1) 3 (1)
Atrial ﬁbrillation 0 (0) 1 (1) 1 (1) 2 (1)
Bacteremia 0 (0) 1 (1) 1 (1) 2 (1)
Blood sodium decreased 1 (1) 0 (0) 1 (1) 2 (1)
Clostridium difﬁcile infection 0 (0) 2 (3) 0 (0) 2 (1)
Deep vein thrombosis 1 (1) 1 (1) 0 (0) 2 (1)
Device-related infection 0 (0) 0 (0) 2 (3) 2 (1)
Diarrhea 1 (1) 1 (1) 0 (0) 2 (1)
Dysphonia 0 (0) 2 (3) 0 (0) 2 (1)
Gastroesophageal reﬂux disease 1 (1) 1 (1) 0 (0) 2 (1)
Hematemesis 0 (0) 0 (0) 2 (3) 2 (1)
Esophageal pain 1 (1) 1 (1) 0 (0) 2 (1)
Esophagitis 1 (1) 0 (0) 1 (1) 2 (1)
Oral herpes 1 (1) 1 (1) 0 (0) 2 (1)
Pulmonary embolism 1 (1) 0 (0) 1 (1) 2 (1)
Salivary duct inﬂammation 1 (1) 1 (1) 0 (0) 2 (1)
NOTE. Events are included without regard to reported causality.
Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse event.
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